SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

BEL 20 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

GALAPAGOS: Click to view the issuer\'s details

Last update : 21/08/2018  >View issuer details

2020.09.29 | 22:01 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial - HTML (w)

2020.09.29 | 22:01 | Permanent Information Releases / General Company News

Dutch version HTML (w) Mail

puce Galapagos kondigt de eerste dosering met Toledo compound GLPG3970 in psoriasis-studie aan - HTML (w)

2020.09.25 | 08:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis - HTML (w)

2020.09.25 | 08:00 | Permanent Information Releases / General Company News

Dutch version HTML (w) Mail

puce Jyseleca®  (filgotinib) goedgekeurd in Japan voor de behandeling van reumatoïde artritis - HTML (w)

2020.09.18 | 22:01 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Galapagos increases share capital through subscription right exercises - HTML (w)

2020.09.18 | 22:01 | Permanent Information Releases / General Company News

Dutch version HTML (w) Mail

puce Galapagos verhoogt kapitaal door uitoefening van inschrijvingsrechten - HTML (w)

2020.09.11 | 04:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Primary endpoint achieved with ziritaxestat  in NOVESA trial in systemic sclerosis patients - HTML (w)

2020.09.11 | 04:30 | Permanent Information Releases / General Company News

Dutch version HTML (w) Mail

puce Primair eindpunt bereikt met ziritaxestat  in NOVESA-studie bij patiënten met systemische sclerose - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 268